结直肠癌k-ras基因与多药耐药相关蛋白相关性研究

摘要

目的：探讨结直肠癌（CRC）中K-ras基因突变和多药耐药相关蛋白的表达及两者的关系。方法：利用免疫组织化学、实时荧光定量PCR技术检测K-ras基因及多药耐药相关蛋白在CRC中的表达。结果：结直肠癌中Pgp、Topo-II、CerbB-2、GST-π和Ki-67的阳性率分别为15.8％，84.21％，26.13％，71.42％，32.67％。 Pgp、Topo-II的表达和K-ras突变率与肿瘤发病的性别、类型、分化程度、浸润深度及有无淋巴结转移无关（P＞0.05），CerbB-2、GST-π的阳性率与肿瘤淋巴结转移相关（P＜0.05），Ki-67的阳性率与肿瘤浸润深度和淋巴结转移相关（P＜0.05）。 K-ras基因突变率为28.94％，与CerbB-2的表达呈正相关（P＜0.05）。结论：联合检测多药耐药相关蛋白及K-ras突变有助于临床判定CRC对化疗药物的敏感性、制定个性化化疗方案提供依据。%Purpose To investigate the expression of the multidrug resistance and K-ras gene mutations in the colorectal cancer and their relationship. Methods:Using Immunohistochemistry and real-time quantitative PCR technique. Results:The expression rate of Pgp , Topo-II , CerbB-2 , GST-π and Ki-67 were 15 . 8%, 84 . 21%, 26 . 13%, 71 . 42%, 32 . 67% in the colorectal cancer . The expression rate of Pgp , Topo-II and K-ras mutation was not significant (P>0 . 05) with tumor incidence of gender , type , differentiation , depth of invasion and lymph node metastasis (P>0 . 05), while CerbB-2 , GST-π was significant with lymph node metastasis (P<0 . 05), Ki-67 was significant with tumor infiltration depth and lymph node metastasis (P<0 . 05). K-ras gene mutation rate was 28 . 94%, and was positively correlated with CerbB-2 expression (P<0 . 05). Conclusion:Combined detection of multidrug resistance- associated protein and K-ras gene mutations can contribute to judgment CRC sensitivity to chemotherapeutic drugs and provide the theory to formulate personalized chemotherapy .